![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/innovent-launches-environmental-social-and-governance-esg-website-to-advance-sustainability-and-corporate-responsibility-302189890.html
https://www.prnewswire.com/news-releases/innovent-announces-oral-presentation-at-the-esmo-gastrointestinal-cancers-congress-2024-on-latest-clinical-data-of-anti-cldn18-2-adc-ibi343-in-patients-with-advanced-gastricgastroesophageal-junction-adenocarcinoma-302186822.html
https://www.prnewswire.com/news-releases/innovent-provides-interpretation-and-updates-on-clinical-data-from-mazdutide-glory-1-study-and-general-biomedicine-pipeline-302184351.html
https://www.fiercebiotech.com/biotech/innovent-braves-bruising-cytokine-space-linking-fusion-protein-tumor-responses-small-study
https://www.prnewswire.com/news-releases/innovent-delivers-oral-presentation-on-clinical-data-of-ibi363-first-in-class-pd-1il-2-bias-bispecific-antibody-fusion-protein-in-advanced-non-small-cell-lung-cancer-and-other-solid-tumors-at-the-2024-esmo-virtual-plenary-302172627.html
https://www.prnewswire.com/news-releases/innovent-to-present-multiple-clinical-study-results-of-mazdutide-at-the-adas-84th-scientific-sessions-302169495.html
https://www.prnewswire.com/news-releases/innovent-receives-fast-track-designation-from-the-us-fda-for-ibi343-topo1i-anti-cldn18-2-adc-as-monotherapy-for-advanced-pancreatic-cancer-302170870.html
https://www.prnewswire.com/news-releases/innovent-delivers-oral-presentation-of-clinical-data-of-a-randomized-controlled-phase-1b-study-evaluating-ibi310-anti-ctla-4-monoclonal-antibody-in-combination-with-sintilimab-as-neoadjuvant-treatment-of-colon-cancer-at-2024-asc-302161380.html